Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, January 29, 2026
REPROCELL announced the launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent.
read more
REPROCELL announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs).
read more
REPROCELL has been producing clinically relevant human induced pluripotent stem cells (hiPSCs) by controlling the process of donor recruitment to seed stock hiPSC and encompassing donor eligibility with different geographical regulatory agencies.
read more
The newly combined CRO specializes in collaborative partnering for global clinical trials.
read more
Thursday, September 07, 2017
According to new industry research more than half of industry professionals believe that the cost of implementing serialization is the greatest hurdle to compliance.
read more
Despite R&D-focused pharmaceutical executives recognizing digital as the primary driver to be more patient-outcome focused, only half of them are currently adopting digital, according to a new report from Accenture.
read more
New industry research reveals that more than one third, 36%, of pharmaceutical manufacturers and contract packagers are not currently preparing for global serialization requirements, despite impending deadlines.
read more
ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has announced research showing many pharmaceutical and clinical research organizations (CROs) support the use ...
read more
Thursday, November 28, 2013
ResearchDx, LLC of Irvine, California, USA today announced an expansion of its operations to focus on the important Indian biopharmaceutical and diagnostics markets.
read more
ResearchDx, LLC of Irvine, California today is pleased to announce the purchase, build-out and relocation to our state of the art 30,000 sq. foot facility in Irvine California. The custom designed facility will support our continued expansion of in ...
read more
Friday, February 07, 2014
Dubai, United Arab Emirates, January 27, 2014 - ResearchDx, LLC of Irvine, California, USA today announced an expansion of its operations to focus on the important Middle East clinical laboratory and diagnostics markets.
read more
ResearchDx, LLC of Irvine, California announced today that it has received a 2013
Strategic Partner Award from WuXi AppTec, Ltd. The award was given in recognition
of the outstanding consulting and personnel services provided to the WuXi AppTec
...
read more
Wednesday, December 02, 2015
Researchers in the Netherlands studying thousands of healthy adults have found a connection between very early stages of brain and heart disease.
read more
Resilience announced it has expanded its strategic partnership with Eli Lilly and Company to increase U.S. production of critical medicines featuring new pharmaceutical manufacturing investments in Ohio.
read more
Tuesday, February 15, 2022
National Resilience, Inc. announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit. As part of the agreement, Resilience will focus on supporting the development and manufacture of multiple products in Takeda’...
read more